Prognostic significance of chronic myocardial injury diagnosed by three different cardiac troponin assays in patients admitted with suspected acute coronary syndrome
© 2023 the author(s), published by De Gruyter, Berlin/Boston..
OBJECTIVES: Chronic myocardial injury (CMI) is defined as stable concentrations of cardiac troponin T or I (cTnT or cTnI) above the assay-specific 99th percentile upper reference limit (URL) and signals poor outcome. The clinical implications of diagnosing CMI are unclear. We aimed to assess prevalence and association of CMI with long-term prognosis using three different high-sensitivity cTn (hs-cTn) assays.
METHODS: A total of 1,292 hospitalized patients without acute myocardial injury had cTn concentrations quantified by hs-cTn assays by Roche Diagnostics, Abbott Diagnostics and Siemens Healthineers. The median follow-up time was 4.1 years. The prevalence of CMI and hazard ratios for mortality and cardiovascular (CV) events were calculated based on the URL provided by the manufacturers and compared to the prognostic accuracy when lower percentiles of cTn (97.5, 95 or 90), limit of detection or the estimated bioequivalent concentrations between assays were used as cutoff values.
RESULTS: There was no major difference in prognostic accuracy between cTnT and cTnI analyzed as continuous variables. The correlation between cTnT and cTnI was high (r=0.724-0.785), but the cTnT assay diagnosed 3.9-4.5 times more patients with having CMI based on the sex-specific URLs (TnT, n=207; TnI Abbott, n=46, TnI Siemens, n=53) and had higher clinical sensitivity and AUC at the URL.
CONCLUSIONS: The prevalence of CMI is highly assay-dependent. cTnT and cTnI have similar prognostic accuracy for mortality or CV events when measured as continuous variables. However, a CMI diagnosis according to cTnT has higher prognostic accuracy compared to a CMI diagnosis according to cTnI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 62(2024), 4 vom: 25. Feb., Seite 729-739 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Steiro, Ole-Thomas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
99th percentile |
|---|
| Anmerkungen: |
Date Completed 27.02.2024 Date Revised 27.02.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2023-0336 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364295619 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364295619 | ||
| 003 | DE-627 | ||
| 005 | 20240229163730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2023-0336 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1308.xml |
| 035 | |a (DE-627)NLM364295619 | ||
| 035 | |a (NLM)37937808 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Steiro, Ole-Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic significance of chronic myocardial injury diagnosed by three different cardiac troponin assays in patients admitted with suspected acute coronary syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2024 | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 the author(s), published by De Gruyter, Berlin/Boston. | ||
| 520 | |a OBJECTIVES: Chronic myocardial injury (CMI) is defined as stable concentrations of cardiac troponin T or I (cTnT or cTnI) above the assay-specific 99th percentile upper reference limit (URL) and signals poor outcome. The clinical implications of diagnosing CMI are unclear. We aimed to assess prevalence and association of CMI with long-term prognosis using three different high-sensitivity cTn (hs-cTn) assays | ||
| 520 | |a METHODS: A total of 1,292 hospitalized patients without acute myocardial injury had cTn concentrations quantified by hs-cTn assays by Roche Diagnostics, Abbott Diagnostics and Siemens Healthineers. The median follow-up time was 4.1 years. The prevalence of CMI and hazard ratios for mortality and cardiovascular (CV) events were calculated based on the URL provided by the manufacturers and compared to the prognostic accuracy when lower percentiles of cTn (97.5, 95 or 90), limit of detection or the estimated bioequivalent concentrations between assays were used as cutoff values | ||
| 520 | |a RESULTS: There was no major difference in prognostic accuracy between cTnT and cTnI analyzed as continuous variables. The correlation between cTnT and cTnI was high (r=0.724-0.785), but the cTnT assay diagnosed 3.9-4.5 times more patients with having CMI based on the sex-specific URLs (TnT, n=207; TnI Abbott, n=46, TnI Siemens, n=53) and had higher clinical sensitivity and AUC at the URL | ||
| 520 | |a CONCLUSIONS: The prevalence of CMI is highly assay-dependent. cTnT and cTnI have similar prognostic accuracy for mortality or CV events when measured as continuous variables. However, a CMI diagnosis according to cTnT has higher prognostic accuracy compared to a CMI diagnosis according to cTnI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 99th percentile | |
| 650 | 4 | |a cardiac troponin I | |
| 650 | 4 | |a cardiac troponin T | |
| 650 | 4 | |a chronic myocardial injury | |
| 650 | 4 | |a prognostic accuracy | |
| 650 | 7 | |a Troponin T |2 NLM | |
| 650 | 7 | |a Troponin I |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Langørgen, Jørund |e verfasserin |4 aut | |
| 700 | 1 | |a Tjora, Hilde L |e verfasserin |4 aut | |
| 700 | 1 | |a Bjørneklett, Rune O |e verfasserin |4 aut | |
| 700 | 1 | |a Skadberg, Øyvind |e verfasserin |4 aut | |
| 700 | 1 | |a Bonarjee, Vernon V S |e verfasserin |4 aut | |
| 700 | 1 | |a Mjelva, Øistein R |e verfasserin |4 aut | |
| 700 | 1 | |a Steinsvik, Trude |e verfasserin |4 aut | |
| 700 | 1 | |a Lindahl, Bertil |e verfasserin |4 aut | |
| 700 | 1 | |a Omland, Torbjørn |e verfasserin |4 aut | |
| 700 | 1 | |a Aakre, Kristin M |e verfasserin |4 aut | |
| 700 | 1 | |a Vikenes, Kjell |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 62(2024), 4 vom: 25. Feb., Seite 729-739 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2024 |g number:4 |g day:25 |g month:02 |g pages:729-739 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2023-0336 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2024 |e 4 |b 25 |c 02 |h 729-739 | ||